The Homax Group

Homax Bio is a clinical-stage biopharmaceutical company specializing in the development of innovative gene therapies for ophthalmic, neurological, and muscular disorders. Headquartered in Suzhou, China, with R&D operations in San Diego, the company leverages its proprietary AAV (Adeno-Associated Virus) vector platform to deliver therapeutic genes to target tissues with high precision. Its lead candidate, HM-001, is currently undergoing Phase 1/2 clinical trials for the treatment of Leber Congenital Amaurosis caused by RPE65 mutations. The company's robust pipeline also includes programs for wet age-related macular degeneration and Duchenne muscular dystrophy, aiming to address significant unmet medical needs through advanced viral vector engineering.